ACADIA Pharmaceuticals Inc. Forecast, price target & analysts
ACADIA Pharmaceuticals Inc. Target price 2026 - Analyst rating & recommendation
ACADIA Pharmaceuticals Inc. Classifications & Recommendation
ACADIA Pharmaceuticals Inc. Price Target
| Target Price | $36.72 |
| Price | $20.68 |
| Potential |
77.56%
register free of charge
|
| Number of Estimates | 22 |
|
22 Analysts have issued a price target ACADIA Pharmaceuticals Inc. 2027 .
The average ACADIA Pharmaceuticals Inc. target price is $36.72.
This is
77.56%
register free of charge
$51.45
148.79%
register free of charge
$17.17
16.97%
register free of charge
|
|
| A rating was issued by 27 analysts: 21 Analysts recommend ACADIA Pharmaceuticals Inc. to buy, 5 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ACADIA Pharmaceuticals Inc. stock has an average upside potential 2027 of
77.56%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 1.07 | 1.30 |
| 11.87% | 21.14% | |
| EBITDA Margin | 10.88% | 9.30% |
| 4.03% | 14.51% | |
| Net Margin | 36.49% | 8.29% |
| 54.34% | 77.28% |
23 Analysts have issued a sales forecast ACADIA Pharmaceuticals Inc. 2026 . The average ACADIA Pharmaceuticals Inc. sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an ACADIA Pharmaceuticals Inc. EBITDA forecast 2026. The average ACADIA Pharmaceuticals Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
23 ACADIA Pharmaceuticals Inc. Analysts have issued a net profit forecast 2026. The average ACADIA Pharmaceuticals Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.30 | 0.63 |
| 69.12% | 72.61% | |
| P/E | 33.06 | |
| EV/Sales | 2.01 |
23 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast for earnings per share. The average ACADIA Pharmaceuticals Inc. EPS is
This results in the following potential growth metrics and future valuations:
ACADIA Pharmaceuticals Inc....
Current ACADIA Pharmaceuticals Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Aug 25 2026 |
| Deutsche Bank |
Locked
➜
Locked
|
Locked | Aug 25 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 25 2026 |
| UBS |
Locked
➜
Locked
|
Locked | Aug 17 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Aug 05 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Aug 25 2026 |
|
Locked
Deutsche Bank:
Locked
➜
Locked
|
Aug 25 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 25 2026 |
|
Locked
UBS:
Locked
➜
Locked
|
Aug 17 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Aug 05 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
